Merck KGaA Expects Modest Growth Ahead Of Launches Next Year
High Hopes For Xenipant And Evobrutinib
Executive Summary
The German firm is eyeing licensing opportunities in 2023 to fill up its mid-stage pipeline.
You may also be interested in...
Merck KGaA’s Oncology Sales And Pipeline Updates Dominate Q3 Earnings
The German firm’s oncology franchise grew to more than €400m in the third quarter as sales of Bavencio doubled, while anticancer partnerships and pipeline updates drew interest.
BTK Inhibitors Are The Next Big Race In MS
BTK inhibitors are in late-stage development for multiple sclerosis, with Merck KgAA and Sanofi in the lead and Roche and Novartis close behind.
Pharma Giants Urge Biotechs To Get In Touch As Early As Possible
Although money is too tight to mention for some biotechs, last year the value of preclinical partnerships actually went up and Switzerland’s big two pharma players are on the lookout for more.